Table III. Disease stage specific activity of IFN-γ in EAE
TreatmentDay of Onset (Mean ± SD)Maximum Score (Mean ± SD)Time to Peak (d) (Mean ± SD)Accumulative Score (Mean ± SD)Incidence (%)Mortality (%)
Before onset
 WT PBS16.1 ± 1.93.8 ± 0.719.5 ± 2.946.1 ± 7.013/13 (100)1a/13 (7.7)
 WT 400 ng IFN-γ15.8 ± 4.04.1 ± 0.221.8 ± 4.546.6 ± 11.55/5 (100)0/5 (0)
 WT 1 μg IFN-γ16.4 ± 2.74.7 ± 1.120.6 ± 3.058.1 ± 26.69/9 (100)3/9 (33.3)
After onset
 WT PBS14.5 ± 3.44.4 ± 1.221.6 ± 4.956.2 ± 26.910/10 (100)3/10 (30)b
 WT 400 ng IFN-γ24.3 ± 4.3c3.6 ± 0.526.5 ± 4.022.1 ± 17.2c4/4 (100)0/4 (0)
 WT 1 μg IFN-γ19.4 ± 5.8c3.9 ± 0.527 ± 2.4c32.8 ± 12.1c9/9 (100)0/9 (0)
  • a Moribund mouse that had to be sacrificed.

  • b A higher mortality was observed within the PBS treated group, perhaps an outcome of the stress induced by daily injections.

  • c p < 0.05, comparison between IFN-γ treatment and PBS treatment.